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microRNA-494 and ATF3 the targets of onconase(?)

Editorial

Zbigniew Darzynkiewicz

Onconase (Onc; also named ranpirnase), a 12 kD
ribonuclease from oocytes of northern leopard frogs (Rana
pipiens), is cytostatic and cytotoxic to variety tumor cell
lines, inhibits growth of tumors in model animals and
advanced to clinical trials as anticancer and antiviral drug
[1]. Although its cytostatic and cytotoxic properties were
recognized nearly three decades ago [2] mechanism of
action is still elusive. The anticancer properties of Onc
require its ribonucleolytic activity sustained by resistance
to ribonuclease inhibitor protein that is present in cytosol
as well as to its remarkable conformational stability.
However, it is unclear which RNA species are preferential
Onc targets whose destruction may explain anticancer
specificity of this RNase. The initial observation that
rRNA and tRNA become degraded in Onc-treated cells
led the authors to propose that suppression of translation
is the primary cause of its activity. However subsequent
observations of cells sensitivity to Onc, its effect on
the cell cycle, and complexity of other effects that lead
to cell death were incompatible with this notion. In fact
the evidence was accumulating that different signaling
pathways become activated and diverse genes were upand down-regulated [3].
In this issue of Oncotarget Vert et al., [4] report on
their attempts to identify the Onc regulated genes that
could explain the cytotoxic and anticancer properties of
this RNase. Using the microarray-derived transcriptional
profiling, confirmed by RT-qPCR, they noticed that among
the up-regulated genes the most conspicuous is activating
transcription factor 3 (ATF3). This was the case for both
ovarian cancer cell lines analyzed by the authors. Together
with up-regulation of several genes downstream of ATF3,
the character of cell cycle changes and other effects
leading to cell apoptosis, the data suggest that activation
of ATF3 is the key event responsible for cytotoxicity of
Onc and for its specificity to cancer cells. Also the prior
studies [3] exploring the up- and down-regulation of
different genes by Onc in malignant mesothelioma cell
lines, conform to these findings. The reported data are also
congruent with the observed antiviral properties of Onc
in as much as this transcription factor can be implicated
in suppressing viral genome replication, keeping virus
latency or preventing viral oncogenesis [4].
The findings that ATF3 is the Onc target are in
accordance with earlier reports that activation of ATF3
by other than Onc means triggers signaling pathways
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that lead to apoptosis in different types of cancers. Of
particular interest are observations that overexpression
of ATF3 increases cell sensitivity to variety of anticancer
drugs. Thus, there is a remarkable correspondence
between the mentioned above effects of ATF3 and Onc
as factors increasing sensitivity of cancer cells to other
treatments. Namely, dozens of papers describing ability of
Onc to sensitize cancer cells to different anticancer drugs
are recorded in PubMed. In some of these publications
Onc is proposed to be used as an adjunctive therapy to
amplify effectiveness of the primary treatment. The
suppression of NF-kB by Onc was advanced to explain its
ability to sensitize cancer cells via decreasing resistance
to apoptosis [5]. The involvement of NF-κB as one of the
mechanisms by which Onc is increasing sensitivity of
cancer cells to other drugs is consistent with up-regulation
of ATF3 as the central event affecting transcription of the
genome of treated cancer cells [4].
The noncoding RNA that provides regulation
of genes activity via RNAi appears to be the potential
primary target of this Onc. It was already demonstrated
that Onc is able to attack siRNA within the cell and
activate the siRNA-suppressed gene [6]. It is possible
therefore that activation of ATF3 by Onc is mediated
by targeting siRNA or other RNAi mechanisms that
otherwise suppress activity of this gene. Thus far the
only candidate that can be found in the literature is
microRNA-494 which by binding to the 3′UTR of ATF3
directly suppresses transcription of this factor. In mice its
overexpression significantly attenuates the level of ATF3
[7]. Perusal of the literature also shows that modulation
of microRNA-494 has profound effects on cancer cells
proliferation and sensitivity to apoptosis. The primary
potential target of Onc, at present, appears to be the
microRNA-494.
Activation of ATF3 via RNAi by Onc does not
preclude the eventuality that other RNA species are targets
of Onc as well. Both rRNA and tRNA have been shown
degraded by Onc. Our early data on human submaxillary
carcinoma A-253 and colon adenocarcinoma Colo 320 CM
cells indicated that in addition to reduced clonogenicity
the size of individual cells as well of cell clones was
substantially smaller in the Onc treated cultures [2].
Also the Onc treated cells had diminished RNA content.
All this suggests that growth rate of the surviving cells
was reduced. This may be expected if rate of translation
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is suppressed by partial targeting rRNA and/or tRNA.
Upon entrance of Onc into the cell, thus, equilibrium may
develop between different rates of degradation of different
RNA species e.g. due to differences of their accessibility
to this RNase. As shown [4] however regardless of the
cell type the dominant effect in terms of a loss of cell
viability appears to be activation of transcription of ATF3.
The data in the literature point out that ATF3 selectivity
may provide its anticancer properties, perhaps across
different cancer types. The antiviral properties of Onc are
also compatible with this mechanism when different RNA
substrates including viral genomes and host-cell nucleic
acids used for viral replication all are accessible to Onc.
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